New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

It lost $9.9M on $1.6M of revenue: $602.87 for every $100. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue1.6100.0%
Cost of revenue0.00.0%
Gross profit1.6100.0%
Research & development−8.3−504.8%
Selling, general & admin−4.2−259.1%
Operating income−10.9−663.9%
Other income, net+1.275.2%
Income tax−0.2−14.1%
Net income−9.9−602.9%
Sep '26 Jun '26 Mar '26 Sep '25 Older periods
Revenue
1.64 1.92 2.23 20.11

+1 more quarter

Gross Profit
1.64 1.92 2.23 20.11
Operating Income
(10.86) (9.39) 2.23 2.16
EBT
(9.63) (6.26) 2.23 1.80
Income after Tax
(9.86) (6.48) 2.23 1.47
Net Income Common
(9.86) (6.48) (17.35) 1.47
EPS (Diluted)
(0.68) (2.62) (7.05) 0.61
Shares (Diluted, Weighted)
14.50 2.48 2.46 2.43
Gross Margin
100.00% 100.00% 100.00% 100.00%
EBIT Margin
(663.94%) (489.83%) 100.00% 10.74%
Net Profit Margin
(602.87%) (337.70%) (776.85%) 7.32%
EBITDA
(10.09) (9.39) 2.23 2.99
EBIT
(10.86) (9.39) 2.23 2.16

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026